Know Cancer

or
forgot password

Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma


N/A
18 Years
N/A
Open (Enrolling)
Both
Follicular Lymphoma

Thank you

Trial Information

Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma


Inclusion Criteria:



- standard radioimmunotherapy with 90-yttrium-labeled anti-CD20-antibodies in
treatment of relapsed and/or refractory follicular NHL or partial remission after
induction chemotherapy

- finding of at least one image-guided measurable lymphoma lesion

- existence of FDG-PET- and CT-image data of at most 8 weeks before treatment

- signed patient´s agreement for RIT registry and MERIT-NHL

Exclusion Criteria:

- other therapy modalities than standard radioimmunotherapy (e.g. consolidation)

- solely CNS-lymphoma or primary effusion lymphoma

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

Evaluation of patient- and lesion specific prognostic factors of radioimmunotherapy

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Carl-Martin Kirsch, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Universitaetsklinikum des Saarlandes

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

MERIT-NHL

NCT ID:

NCT01151358

Start Date:

May 2008

Completion Date:

December 2011

Related Keywords:

  • Follicular Lymphoma
  • radioimmunotherapy
  • follicular non-Hodgkin´s lymphoma
  • FDG-PET
  • prognostic factors
  • multicenter study
  • Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin

Name

Location